Reviewed listing: NASDAQ:CLBT · Analysis dated Oct 28, 2026
How does the company make money?
Cellebrite sells software that police and other organizations use to extract data, for example from mobile phones, and search it for investigations. It earns primarily from ongoing subscriptions and maintenance contracts.
What supports the business?
In the second quarter, the annual value of ongoing subscriptions and maintenance contracts rose 21 percent to 507.8 million US dollars. This shows that contracts with existing customers continue to grow.
What could improve?
If Cellebrite achieves shorter sales cycles and existing customers expand their contracts, the annual value of recurring subscriptions could continue to grow. This remains a possibility, not an assured trend.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At the specified price of 11.92 US dollars, it is not possible to reliably say whether the stock is cheap or expensive. The lowered annual forecast and lower quarterly earnings make a reliable valuation more difficult.
What is the main risk?
Longer sales processes and fewer customers switching to a new offering dampened expectations; quarterly earnings also fell, and Cellebrite lowered its full-year guidance. On August 13, 2026, Shiven Ramji replaced Thomas E. Hogan as CEO with immediate effect—the leadership change therefore took place during this weaker performance.
What is the overall assessment?
Cellebrite sells software for digital investigations and is generating growing recurring contract revenue. Offsetting this are a sharply lower quarterly profit, weaker cash inflow in the first half, and a reduced full-year forecast. At the given price, the valuation cannot be assessed reliably; a justified opportunity therefore does not currently emerge.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in